Minireview: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers

Molecular Endocrinology

Volumn 26, Issue 3, 2012, Pages 360-371

  Baumgarten, Sarah C ^a   Frasor, Jonna ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROSTAGLANDIN E SYNTHASE 1; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT3 PROTEIN; STEROID RECEPTOR COACTIVATOR 3; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER INVASION; CANCER PROGNOSIS; CANCER RISK; CELL PROLIFERATION; CELL STRAIN MCF 7; CYTOKINE PRODUCTION; DNA BINDING; ESTROGEN RESPONSIVE ELEMENT; ESTROGEN SYNTHESIS; HUMAN; INFLAMMATION; INVOLUTION; MAMMARY GLAND; METASTASIS; MOLECULAR INTERACTION; OBESITY; OVERALL SURVIVAL; PREGNANCY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; BREAST NEOPLASMS; CYTOKINES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; PREGNANCY; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 84857478156     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2011-1302     Document Type: Review

References (133)

1. Clarke R, Leonessa F, Welch JN, Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
2. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316-7339
3. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
4. Loi S, Piccart M, Sotiriou C 2007 The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Crit Rev Oncol Hematol 61:187-194
5. Huang L, Zhao S, Frasor JM, Dai Y 2011 An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One 6:e22274
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, Botstein D 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
7. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167
8. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ 2010 A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232
9. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
10. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer Jr CE, Wickerham DL, Wolmark N 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 24:3726-3734
11. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF 2010 Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
12. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM 2003 Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21: 1973-1979
13. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R 2010 Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12:R40
14. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ 1992 Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective southwest oncology group study. J Clin Oncol 10:1284-1291
15. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R 2009 Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 114:287-299
16. Musgrove EA, Sutherland RL 2009 Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631-643
17. Ellis MJ, Tao Y, Young O, White S, Proia AD, Murray J, Renshaw L, Faratian D, Thomas J, Dowsett M, Krause A, Evans DB, Miller WR, Dixon JM 2006 Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24:3019-3025
18. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM 2004 HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10: 5670-5676
19. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S 2005 A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748
20. Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S 2003 Elevated protein kinaseCα expression may be predictive of tamoxifen treatment failure. Br J Cancer 88:1400-1402
21. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM 2005 AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139-146
22. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV 2008 Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 26:4078-4085
23. Miller TW, Balko JM, Arteaga CL 2011 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29:4452-4461
24. Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL 2011 A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71:6773-6784
25. Hanahan D, Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144:646-674
26. Grivennikov SI, Greten FR, Karin M 2010 Immunity, inflammation, and cancer. Cell 140:883-899
27. Coussens LM, Werb Z 2002 Inflammation and cancer. Nature 420:860-867
28. Ben-Neriah Y, Karin M 2011 Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12:715-723
29. Ouchi N, Parker JL, Lugus JJ, Walsh K 2011 Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85-97
30. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI 2004 Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433-2440
31. Bruunsgaard H, Pedersen M, Pedersen BK 2001 Aging and proinflammatory cytokines. Curr Opin Hematol 8:131-136
32. Pfeilschifter J, Köditz R, Pfohl M, Schatz H 2002 Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23:90-119
33. Schedin P 2006 Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6:281-291
34. Bladström A, Anderson H, Olsson H 2003 Worse survival in breast cancer among women with recent childbirth: results from a Swedish population-based register study. Clin Breast Cancer 4:280-285
35. Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA 2004 Reproductive history and mortality after breast cancer diagnosis. Obstet Gynecol 104:146-154
36. Monks J, Geske FJ, Lehman L, Fadok VA 2002 Do inflammatory cells participate in mammary gland involution? J Mammary Gland Biol Neoplasia 7:163-176
37. Asztalos S, Gann PH, Hayes MK, Nonn L, Beam CA, Dai Y, Wiley EL, Tonetti DA 2010 Gene expression patterns in the human breast after pregnancy. Cancer Prev Res 3:301-311
38. O'Brien J, Schedin P 2009 Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? J Mammary Gland Biol Neoplasia 14:145-157
39. Connelly L, Barham W, Pigg R, Saint-Jean L, Sherrill T, Cheng DS, Chodosh LA, Blackwell TS, Yull FE 2010 Activation of nuclear factor κB in mammary epithelium promotes milk loss during mammary development and infection. J Cell Physiol 222:73-81
40. Brantley DM, Yull FE, Muraoka RS, Hicks DJ, Cook CM, Kerr LD 2000 Dynamic expression and activity of NF-κB during postnatal mammary gland morphogenesis. Mech Dev 97:149-155
41. Pensa S, Watson CJ, Poli V 2009 Stat3 and the inflammation/acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia 14:121-129
42. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P 2006 Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am J Pathol 168:608-620
43. Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC, Schedin P 2011 Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 17:1109-1115
44. Phillips KA, Milne RL, Friedlander ML, Jenkins MA, McCredie MR, Giles GG, Hopper JL 2004 Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol 22: 699-705
45. Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL 2002 The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev 11:235-241
46. Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH 2001 Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol 79:41-47
47. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER 1996 Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739-5742
48. Brown KA, Simpson ER 2010 Obesity and breast cancer: progress to understanding the relationship. Cancer Res 70:4-7
49. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D 2007 Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 335:1134
50. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A 2002 Obesity, body size, and risk of postmenopausal breast cancer: the women's health initiative (United States). Cancer Causes Control 13:741-751
51. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE, Willett WC 1997 Dual effects of weight and weight gain on breast cancer risk. JAMA 278:1407-1411
52. Feigelson HS, Patel AV, Teras LR, Gansler T, Thun MJ, Calle EE 2006 Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer 107:12-21
53. Giuffrida D, Lupo L, La Porta GA, La Rosa GL, Padova G, Foti E, Marchese V, Belfiore A 1992 Relation between steroid receptor status and body weight in breast cancer patients. Eur J Cancer 28:112-115
54. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J 2010 Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415
55. Cai D 2009 NFκB-mediated metabolic inflammation in peripheral tissues versus central nervous system. Cell Cycle 8:2542-2548
56. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, Dannenberg AJ 2011 Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 4:329-346
57. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannenberg AJ 2011 Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4:1021-1029
58. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S 2006 Quantitative analysis of aromatase mRNA expression derived from various promoters (I. 4, I. 3, PII and I. 7) and its association with expression of TNF-α, IL-6 and COX-2 mRNAs in human breast cancer. Int J Cancer 118:1915-1921
59. Zhao Y, Nichols JE, Valdez R, Mendelson CR, Simpson ER 1996 Tumor necrosis factor-α stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol 10:1350-1357
60. Cleary MP, Grossmann ME 2009 Minireview: obesity and breast cancer: the estrogen connection. Endocrinology 150:2537-2542
61. Kelly PM, Davison RS, Bliss E, McGee JO 1988 Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer 57:174-177
62. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL 1996 Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625-4629
63. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW 2003 Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113-2126
64. Lin EY, Nguyen AV, Russell RG, Pollard JW 2001 Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727-740
65. Steele RJ, Eremin O, Brown M, Hawkins RA 1986 Oestrogen receptor concentration and macrophage infiltration in human breast cancer. Eur J Surg Oncol 12:273-276
66. Mor G, Yue W, Santen RJ, Gutierrez L, Eliza M, Berstein LM, Harada N, Wang J, Lysiak J, Diano S, Naftolin F 1998 Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 67:403-411
67. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR 2005 Macrophages induce invasiveness of epithelial cancer cells via NF-κB and JNK. J Immunol 175:1197-1205
68. Zhang GJ, Adachi I 1999 Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19:1427-1432
69. Knüpfer H, Preiss R 2007 Significance of interleukin-6 (IL-6) in breast cancer. Breast Cancer Res Treat 102:129-135 (Review)
70. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM 2007 Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer. FASEB J 21:3763-3770
71. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N, Oberyszyn TM, HallBM2009 Interleukin-6 induces an epithelialmesenchymal transition phenotype in human breast cancer cells. Oncogene 28:2940-2947
72. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S, Huang T, Chan MW, Marini FC, Rosol TJ, Bonafé M, Hall BM 2008 Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 68:9087-9095
73. Walter M, Liang S, Ghosh S, Hornsby PJ, Li R 2009 Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 28:2745-2755
74. Goldberg JE, Schwertfeger KL 2010 Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11:1133-1146
75. Speirs V, Kerin MJ, Newton CJ, Walton DS, Green AR, Desai SB, Atkin SL 1999 Evidence for transcriptional activation of ERα by IL-1β in breast cancer cells. Int J Oncol 15:1251-1254
76. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol PF, Glass CK, Rosenfeld MG, Rose DW 2006 Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124:615-629
77. Keeton EK, Brown M 2005 Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-α and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 19:1543-1554
78. Franco-Barraza J, Valdivia-Silva JE, Zamudio-Meza H, Castillo A, García-Zepeda EA, Benítez-Bribiesca L, Meza I 2010 Actin cytoskeleton participation in the onset of IL-1β induction of an invasive mesenchymal-like phenotype in epithelial MCF-7 cells. Arch Med Res 41:170-181
79. Wang FM, Liu HQ, Liu SR, Tang SP, Yang L, Feng GS 2005 SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1β in vivo and in vitro. Breast Cancer Res Treat 89:5-14
80. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N 2000 Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2:252-257
81. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF 1997 Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 43:211-215
82. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR 1994 Expression of tumour necrosis factor (TNFα) and its receptors in benign and malignant breast tissue. Int J Cancer 56:777-782
83. Simstein R, Burow M, Parker A, Weldon C, Beckman B 2003 Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med 228:995-1003
84. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, Charreau EH, Frahm I, Sapia S, Brouckaert P, Elizalde PV, Schillaci R 2008 TNFα acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-κB-dependent pathways. Exp Cell Res 314:509-529
85. Rubio MF, Werbajh S, Cafferata EG, Quaglino A, Coló GP, Nojek IM, Kordon EC, Nahmod VE, Costas MA 2006 TNF-α enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-κB. Oncogene 25:1367-1377
86. Yin Y, Chen X, Shu Y 2009 Gene expression of the invasive phenotype of TNF-α-treated MCF-7 cells. Biomed Pharmacother 63: 421-428
87. Mosaffa F, Lage H, Afshari JT, Behravan J 2009 Interleukin-1β and tumor necrosis factor-α increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX. Inflamm Res 58:669-676
88. Pradhan M, Bembinster LA, Baumgarten SC, Frasor J 2010 Proinflammatory cytokines enhance estrogen-dependent expression of the multidrug transporter gene ABCG2 through estrogen receptor and NFκB cooperativity at adjacent response elements. J Biol Chem 285:31100-31106
89. Krishnamurthy P, Schuetz JD 2006 Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol 46:381-410
90. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS 2003 Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144:4562-4574
91. Hah N, Danko CG, Core L, Waterfall JJ, Siepel A, Lis JT, Kraus WL 2011 A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells. Cell 145:622-634
92. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M 2006 Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38:1289-1297
93. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, Yeo A, George J, Kuznetsov VA, Lee YK, Charn TH, Palanisamy N, Miller LD, Cheung E, Katzenellenbogen BS, Ruan Y, Bourque G, Wei CL, Liu ET 2007 Whole-genome cartography of estrogen receptor α binding sites. PLoS Genet 3:e87
94. Karin M 2006 Nuclear factor-κB in cancer development and progression. Nature 441:431-436
95. Bonizzi G, Karin M 2004 The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288
96. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M 2001 IKKα provides an essential link betweenRANK signaling and cyclin D1 expression during mammary gland development. Cell 107:763-775
97. Gloire G, Dejardin E, Piette J 2006 Extending the nuclear roles of IκB kinase subunits. Biochem Pharmacol 72:1081-1089
98. Park KJ, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB 2005 Formation of an IKKα-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18:71-82
99. Tu Z, Prajapati S, Park KJ, Kelly NJ, Yamamoto Y, Gaynor RB 2006 IKKα regulates estrogen-induced cell cycle progression by modulating E2F1 expression. J Biol Chem 281:6699-6706
100. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE 1997 Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 100: 2952-2960
101. Jones RL, Rojo F, A'Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho JS, Dowsett M, Albanell J 2011 Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol 64:130-135
102. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD 2004 NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101:10137-10142
103. Hardy DB, Janowski BA, Chen CC, Mendelson CR 2008 Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligandindependent mechanisms. Mol Endocrinol 22:1812-1824
104. Kobayashi S, Stice JP, Kazmin D, Wittmann BM, Kimbrel EA, Edwards DP, Chang CY, McDonnell DP 2010 Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. Mol Endocrinol 24:2292-2302
105. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, Benz CC 2005 Activation of nuclear factor-κB (NFκB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37:1130-1144
106. deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR 2004 NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 15:885-890
107. Riggins RB, Zwart A, Nehra R, Clarke R 2005 The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 4:33-41
108. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, Lin CY, Stanculescu A 2009 Positive cross-talk between estrogen receptor and NF-κB in breast cancer. Cancer Res 69:8918-8925
109. Straub RH 2007 The complex role of estrogens in inflammation. Endocr Rev 28:521-574
110. Kalaitzidis D, Gilmore TD 2005 Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends Endocrinol Metab 16: 46-52
111. Sun WH, Keller ET, Stebler BS, Ershler WB 1998 Estrogen inhibits phorbol ester-induced IκBκ transcription and protein degradation. Biochem Biophys Res Commun 244:691-695
112. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge Jr GW 1997 Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639
113. Galien R, Garcia T 1997 Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-κB site. Nucleic Acids Res 25:2424-2429
114. Stein B, Yang MX 1995 Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBPβ. Mol Cell Biol 15:4971-4979
115. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE 2007 Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9:470-478
116. Quaedackers ME, van den Brink CE, van der Saag PT, Tertoolen LG 2007 Direct interaction between estrogen receptor α and NF-κB in the nucleus of living cells. Mol Cell Endocrinol 273: 42-50
117. Gionet N, Jansson D, Mader S, Pratt MA 2009 NF-κB and estrogen receptor α interactions: differential function in estrogen receptor-negative and-positive hormone-independent breast cancer cells. J Cell Biochem 107:448-459
118. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC 2006 Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 21:555-564
119. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK 2000 The role of CBP in estrogen receptor cross-talk with nuclear factor-κB in HepG2 cells. Endocrinology 141:3403-3411
120. Nettles KW, Gil G, Nowak J, Métivier R, Sharma VB, Greene GL 2008 CBP Is a dosage-dependent regulator of nuclear factor-κB suppression by the estrogen receptor. Mol Endocrinol 22:263-272
121. Speir E, Yu ZX, Takeda K, Ferrans VJ, Cannon 3rd RO 2000 Competition for p300 regulates transcription by estrogen receptors and nuclear factor-κB in human coronary smooth muscle cells. Circ Res 87:1006-1011
122. Bodine PV, Harris HA, Komm BS 1999 Suppression of liganddependent estrogen receptor activity by bone-resorbing cytokines in human osteoblasts. Endocrinology 140:2439-2451
123. Feldman I, Feldman GM, Mobarak C, Dunkelberg JC, Leslie KK 2007 Identification of proteins within the nuclear factor-κB transcriptional complex including estrogen receptor-α. Am J Obstet Gynecol 196:394 e391-311; discussion 394 e311-393
124. Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ 2004 Transrepression of estrogen receptor β signaling by nuclear factor-κb in ovarian granulosa cells. Mol Endocrinol 18:1919-1928
125. Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, Chalbos D, Sonenshein GE 2009 RelB NF-κB represses estrogen receptor α expression via induction of the zinc finger protein Blimp1. Mol Cell Biol 29:3832-3844
126. Park JY, Pillinger MH, Abramson SB 2006 Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119:229-240
127. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T 2004 Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101:591-596
128. Larkins TL, Nowell M, Singh S, Sanford GL 2006 Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 6:181
129. Chang SH, Ai Y, Breyer RM, Lane TF, Hla T 2005 The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res 65:4496-4499
130. Frasor J, Weaver AE, Pradhan M, Mehta K 2008 Synergistic upregulation of prostaglandin E synthase expression in breast cancer cells by 17β-estradiol and proinflammatory cytokines. Endocrinology 149:6272-6279
131. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J 2010 Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Cancer 1:127-135
132. Pradhan M, Baumgarten SC, Bembinster LA, Frasor J 14 November 2011 CBP medites NFκB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter. Mol Cell Biol 10.1128/MCB. 05869-11
133. Weitsman GE, Li L, Skliris GP, Davie JR, Ung K, Niu Y, Curtis-Snell L, Tomes L, Watson PH, Murphy LC 2006 Estrogen receptor-α phosphorylated at Ser118 is present at the promoters of estrogen-regulated genes and is not altered due to HER-2 overexpression. Cancer Res 66:10162-10170